Novo Nordisk predicts period of "different" growth when semaglutide patents expire
![Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13595289.ece/ALTERNATES/schema-16_9/doc7j17kalxrg01kyimkf0u.jpg)
When patents related to Novo Nordisk's bestselling GLP-1 molecule, semaglutide, expire, it might affect the company's growth, CEO at Novo Nordisk Lars Fruergaard Jørgensen tells Danish business daily Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.